Childhood non-Hodgkin lymphoma

Hematological Malignancies: In Children, Adolescents and Young Adults

Volumn , Issue , 2012, Pages 299-328

  Pinkerton, Ross ^a   Cairo, Mitchell S ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84973171100     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789814299619_0016     Document Type: Chapter

References (60)

1. Anderson JR, Wilson JF, Jenkin DT, Meadows AT, Kersey J, Chilcote RR, Coccia P, Exelby P, Kushner J, Siegel S, Hammond D. (1983) Childhood non-Hodgkin’s lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 308: 559–565.
2. Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Kurtzberg J, Desai S, Camitta B, Murphy SB. (1999) Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. Leukemia 13: 335–342.
3. Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, Mann G, Chott A, Ebell W, Klingebiel T, Graf N, Kremens B, Muller-Weihrich S, Pluss HJ, Zintl F, Henze G, Riehm H. (1999) Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 94: 3294–3306.
4. Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, Klapper W, Wacker HH, Ludwig WD, Niggli F, Mann G, Gadner H, Riehm H, Schrappe M, Reiter A. (2007) Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin’s lymphoma differ by non-Hodgkin’s lymphoma subtype: A Berlin-Frankfurt- Munster Group Report. J Clin Oncol 25: 3915–3922.
5. Spreafico F, Massimino M, Luksch R, Casanova M, Cefalo GS, Collini P, Ferrari A, Polastri D, Terenziani M, Gasparini M, Fossati-Bellani F. (2002) Intensive, very short-term chemotherapy for advanced Burkitt’s lymphoma in children. J Clin Oncol 20: 2783–2788.
6. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, Weston C, Perkins SL, Raphael M, McCarthy K, Patte C. (2007) Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 109: 2736–2743.
7. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS. (2007) Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients. Blood 109: 2773–2780.
8. Amos Burke GA, Imeson J, Hobson R, Gerrard M. (2003) Localized non-Hodgkin’s lymphoma with B-cell histology: Cure without cyclophosphamide? A report of the United Kingdom Children’s Cancer Study Group on studies NHL 8501 and NHL 9001 (1985–1996). Br J Haematol 121: 586–591.
9. Gerrard M, Cairo MS, Weston C, Auperin A, Pinkerton R, Lambilliote A, Sposto R, McCarthy K, Lacombe MJ, Perkins SL, Patte C. (2008) Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non- Hodgkin’s lymphoma: Results of the FAB/LMB 96 international study. Br J Haematol 141: 840–847.
10. Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A. (2005) The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: A report of the BFM Group Study NHLBFM95. Blood 105: 948–958.
11. Reiter A, Klapper W. (2008) Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Haematol 142: 329–347.
12. Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, Tarbell N, Desai S, Weitzman S, Weinstein HJ, Murphy SB. (2005) Advanced-stage large-cell lymphoma in children and adolescents: Results of a randomized trial incorporating intermediate- dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: A Pediatric Oncology Group phase III trial. J Clin Oncol 23: 541–547.
13. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7: 379–391.
14. Sandlund JT, Santana VM, Hudson MM, Onciu M, Head D, Murry DJ, Ribeiro R, Wallace D, Rencher R, Pui CH. (2008) Combination of dexamethasone, highdose cytarabine, and carboplatin is effective for advanced large-cell non-Hodgkin lymphoma of childhood. Cancer 113: 782–790.
15. Lones MA, Perkins SL, Sposto R, Kadin ME, Kjeldsberg CR, Wilson JF, Cairo MS. (2000) Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: A Children’s Cancer Group report. J Clin Oncol 18: 3845–3853.
16. Seidemann K, Tiemann M, Lauterbach I, Mann G, Simonitsch I, Stankewitz K, Schrappe M, Zimmermann M, Niemeyer C, Parwaresch R, Riehm H, Reiter A. (2003) Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: Treatment and results from three therapeutic studies of the Berlin-Frankfurt-Munster Group. J Clin Oncol 21: 1782–1789.
17. Attias D, Hodgson D, Weitzman S. (2009) Primary mediastinal B-cell lymphoma in the pediatric patient: Can a rational approach to therapy be based on adult studies? Pediatr Blood Cancer 52: 566–570.
18. le Deley MC, Reiter A, Williams D, Delsol G, Oschlies I, McCarthy K, Zimmermann M, Brugieres L. (2008) Prognostic factors in childhood anaplastic large cell lymphoma: Results of a large European intergroup study. Blood 111: 1560–1566.
19. Rosolen A, Pillon M, Garaventa A, Burnelli R, d’Amore ES, Giuliano M, Comis M, Cesaro S, Tettoni K, Moleti ML, Tamaro P, Visintin G, Zanesco L. (2005) Anaplastic large cell lymphoma treated with a leukemia-like therapy: Report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer 104: 2133–2140.
20. Lowe EJ, Sposto R, Perkins SL, Gross TG, Finlay J, Zwick D, Abromowitch M. (2009) Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of Children’s Cancer Group Study 5941. Pediatr Blood Cancer 52: 335–339.
21. Brugieres L, le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, Mann G, Zsiros J, Uyttebroeck A, Marky I, Lamant L, Reiter A. (2009) Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: Results of a randomized trial of the EICNHL Group. J Clin Oncol 27: 897–903.
22. Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, Schirg E, Henze G, Schellong G, Gadner H, Riehm H. (2000) Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM group report. Blood 95: 416–421.
23. Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, Mann G, Henze G, Niggli F, Ludwig WD, Janssen D, Riehm H, Schrappe M, Reiter A. (2006) Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 24: 491–499.
24. Pillon M, Piglione M, Garaventa A, Conter V, Giuliano M, Arcamone G, Mura R, Cellini M, D’Amore ES, Varotto S, Mussolin L, Rosolen A. (2009) Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: A report of the Italian Association of Pediatric Hematology and Oncology. Pediatr Blood Cancer 53: 953–959.
25. Abromowitch M, Sposto R, Perkins S, Zwick D, Siegel S, Finlay J, Cairo MS. (2008) Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: Report from the Children’s Oncology Group. Br J Haematol 143: 261–267.
26. Sandlund JT, Pui CH, Zhou Y, Behm FG, Onciu M, Razzouk BI, Hijiya N, Campana D, Hudson MM, Ribeiro RC. (2009) Effective treatment of advancedstage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: Results of St Jude NHL13 study. Leukemia 23: 1127–1130.
27. Windsor R, Stiller C, Webb D. (2008) Peripheral T-cell lymphoma in childhood: Population-based experience in the United Kingdom over 20 years. Pediatr Blood Cancer 50: 784–787.
28. Nelson M, Horsman DE, Weisenburger DD, Gascoyne RD, Dave BJ, Loberiza FR, Ludkovski O, Savage KJ, Armitage JO, Sanger WG. (2008) Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. Br J Haematol 141: 461–469.
29. Zettl A, Rudiger T, Konrad MA, Chott A, Simonitsch- Klupp I, Sonnen R, Muller-Hermelink HK, Ott G. (2004) Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 164: 1837–1848.
30. Hutchison RE, Laver JH, Chang M, Muzzafar T, Desai S, Murphy S, Schwenn M, Shuster J, Link MP. (2008) Non-anaplastic peripheral t-cell lymphoma in childhood and adolescence: A Children’s Oncology Group study. Pediatr Blood Cancer 51: 29–33.
31. Paolo C, Lucia F, Anna D. (2007) Hematopoietic stem cell transplantation in peripheral T-cell lymphomas. Leuk Lymphoma 48: 1496–1501.
32. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, Gianni AM, Rambaldi A, Barbui T, Cortelazzo S. (2006) Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20: 1533–1538.
33. Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, Narni F, Patriarca F, Boccadoro M, Benedetti F, Rambaldi A, Gianni AM, Tarella C. (2004) Graftversus- lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22: 2172–2176.
34. Pickhardt PJ, Siegel MJ, Hayashi RJ, Kelly M. (2000) Posttransplantation lymphoproliferative disorder in children: Clinical, histopathologic, and imaging features. Radiology 217: 16–25.
35. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, Lennette ET, Martinez OM, Krams SM, Berquist WE, So SK, Esquivel CO. (1995) An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 59: 524–529.
36. Opelz G, Henderson R. (1993) Incidence of non- Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342: 1514–1516.
37. Webber SA, Naftel DC, Fricker FJ, Olesnevich P, Blume ED, Addonizio L, Kirklin JK, Canter CE. (2006) Lymphoproliferative disorders after paediatric heart transplantation: A multi-institutional study. Lancet 367: 233–239.
38. Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P, Fischer A, Morschhauser F, Salles G, Feremans W, Vilmer E, Peraldi MN, Lang P, Lebranchu Y, Oksenhendler E, Garnier JL, Lamy T, Jaccard A, Ferrant A, Offner F, Hermine O, Moreau A, Fafi-Kremer S, Morand P, Chatenoud L, Berriot-Varoqueaux N, Bergougnoux L, Milpied N. (2006) Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 107: 3053–3057.
39. Messahel B, Taj MM, Hobson R, Hadzic N, Ramsay A, Hann I, Pinkerton R. (2006) Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: A United Kingdom Children’s Cancer Study Group (UKCCSG) retrospective review. Leuk Lymphoma 47: 2584–2589.
40. Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, Lynch JC. (2005) Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 23: 6481–6488.
41. Orjuela M, Gross TG, Cheung YK, Alobeid B, Morris E, Cairo MS. (2003) A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 9: 39455-39525.
42. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE. (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein- Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92: 1549–1555.
43. Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE. (2008) Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 26: 2717–2724.
44. Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, Shiramizu B, Wiley J, Woods D, Barnich M, Gross TG. (2009) A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: A report from the Children’s Oncology Group. Pediatr Blood Cancer 52: 177–181.
45. Cooney-Qualter E, Krailo M, Angiolillo A, Fawwaz RA, Wiseman G, Harrison L, Kohl V, Adamson PC, Ayello J, vande Ven C, Perkins SL, Cairo MS. (2007) A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin’s lymphoma: A Children’s Oncology Group study. Clin Cancer Res 13: 56525–56605.
46. Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ, Goldenberg DM. (2007) Epratuzumab, a CD22- targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 44: 1331–1341.
47. Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WA, Horak ID, Goldenberg DM. (2005) Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol 23: 5044–5051.
48. Strauss SJ, Morschhauser F, Rech J, Repp R, Solal- Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA. (2006) Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol 24: 3880–3886.
49. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, Reid JM, Goldenberg DM, Wegener WA, Carroll WL, Adamson PC. (2008) Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A Children’s Oncology Group Pilot Study. J Clin Oncol 26: 3756–3762.
50. Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, Bosly A, Pinter-Brown L, Kennedy D, Sievers EL, Gopal AK. (2009) A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 146: 171–179.
51. Miles RR, Cairo MS, Satwani P, Zwick DL, Lones MA, Sposto R, Abromovitch M, Tripp S, Angiolillo AL, Roman E, Davenport V, Perkins SL. (2007) Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: A children’s oncology group report. Br J Haematol 138: 506–512.
52. Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, Levis A, Manna A, Secondo V, Rigacci L, Pinto A, Iannitto E, Zoli V, Torchio P, Pileri S, Tarella C. (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110: 2316–2323.
53. Attarbaschi A, Dworzak M, Steiner M, Urban C, Fink FM, Reiter A, Gadner H, Mann G. (2005) Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: A population-based analysis of the Austrian Cooperative Study Group. Pediatr Blood Cancer 44: 70–76.
54. Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, Lakomek M, Henze G, von Stackelberg A. (2009) Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: A report from the Berlin-Frankfurt- Muenster Group. J Clin Oncol 27: 3363–3369.
55. Woessmann W, Peters C, Lenhard M, Burkhardt B, Sykora KW, Dilloo D, Kremens B, Lang P, Fuhrer M, Kuhne T, Parwaresch R, Ebell W, Reiter A. (2006) Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents — a Berlin-Frankfurt- Munster group report. Br J Haematol 133: 176–182.
56. Brugieres L, Pacquement H, le Deley MC, Leverger G, Lutz P, Paillard C, Baruchel A, Frappaz D, Nelken B, Lamant L, Patte C. (2009) Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: A report from the French Society of Pediatric Oncology. J Clin Oncol 27: 5056–5061.
57. Stockklausner C, Behnisch W, Mechtersheimer G, Moller P, Kulozik AE. (2008) Long-term remission of children with relapsed and secondary anaplastic large cell non-Hodgkin lymphoma (ALCL) following treatment with pulsed dexamethasone and low dose etoposide. Pediatr Blood Cancer 50: 126–129.
58. Levine JE, Harris RE, Loberiza FR, Armitage JO, Vose JM, van Besien K, Lazarus HM, Horowitz MM, Bashey A, Bolwell BJ, Burns LJ, Cairo MS, Champlin RE, Freytes CO, Gibson J, Goldstein SC, Laughlin MJ, Lister J, Marks DI, Maziarz RT, Miller AM, Milone GA, Pavlovsky S, Pecora AL, Rizzo JD, Schiller G, Schouten HC, Zhang MJ. (2003) A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101: 2476–2482.
59. Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS, Hayashi RJ, Termuhlen AM, Zhang MJ, Davies SM, Eapen M. (2009) Hematopoietic stem cell transplantation for refractory or recurrent nonhodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant.
60. Shankar A, Fiumara F, Pinkerton R. (2008) Role of FDG PET in the management of childhood lymphomas — case proven or is the jury still out? Eur J Cancer 44: 663–673.